Merck Invests €50 million in Netherlands Facility
U.S. pharmaceutical company expands biotech manufacturing plant in Oss
Merck & Co., known as Merck Sharp & Dohme (MSD) in the Netherlands, will expand its manufacturing plant in Oss. The €50 million investment will allow the company to increase its current biotech manufacturing production in the city. Merck’s expansion will create 30 new jobs in addition to facility’s 400 existing employees. Over the past several years, the company invested roughly €220 million in North Brabant.
“Thanks to the fact that our facilities are in Brabant – one the most concentrated life sciences clusters in the world with a strong presence of biotech and engineering universities – I am convinced that we will always be able to attract talented and highly skilled people,” said Trinette Stolle of MSD Biotech in Oss.
Strategic location for expansion
MSD’s expansion in the Netherlands is a strategic decision by Merck. The country has one of the most concentrated life sciences regions in the world. In fact, Holland is home to more than 2,500 innovative life sciences and health companies and research organizations. Within a 120-mile radius there is a cluster of 360 of those innovative life sciences companies. Major multinational companies in the country include Boston Scientific, Stryker, Astellas, GlaxoSmithKline and Medtronic.
The region is also fueled by world-class health and research institutes, including 12 research universities and 82 hospitals. Each year, there is more than €2 billion in life sciences R&D investment. Holland’s high-quality infrastructure, tax support measures and pro-business climate provide companies such as MSD with an excellent environment for expansion.
Source: Het Financieele Dagblad